Mymee Inc is a pioneering brand that specializes in personalized trials and care for patients with autoimmune diseases and long COVID. With over 1,000 completed personalized trials, Mymee is dedicated to transforming autoimmune care and providing individuals with the tools they need to take control of their disease. The brand's founder, Mette Dyhrberg, experienced firsthand the challenges of living with autoimmune diagnoses, including psoriatic arthritis and Sjögren’s syndrome.

Frustrated by traditional treatments, she took matters into her own hands and developed a method to analyze her own data, identifying triggers that correlated with her flares. This breakthrough led to her own remission and inspired her to help others. Since its founding in 2017, Mymee's award-winning personalized trial platform has been clinically validated and continues to make a difference in the lives of patients.

In 2020, the brand expanded its research and care to include long COVID, and in 2022, it acquired Breakthrough Health, further enhancing its capabilities. Mymee firmly believes that personalized trials and care should be accessible to everyone, as there is no universal cure or treatment for autoimmune diseases. The brand's commitment to empowering individuals with self-evidence-based solutions sets it apart in the industry.

To learn more about Mymee and its transformative approach to autoimmune care, visit their website or get in touch with their team